BMO Downgrades Gilead Sciences (GILD) to Market Perform
More News related to GILD
- Gilead Sciences to Present at the NASDAQ OMX 23rd Investor Program
- Gilead Sciences (GILD) and Glaxo (GSK) Agree to Commercialize Viread Hep B Treatment in Five Asian Countries
- Gilead and GlaxoSmithKline Announce Agreement to Commercialize Viread(R) for Chronic Hepatitis B in Key Asian Countries
- 2010 IR Global Rankings: Invitation for Investors and Analysts Vote for Companies with the Best IR Program and for the Best IR Officer
- Gilead Sciences to Present at the Lazard Capital Markets 6TH Annual Healthcare Conference on Tuesday, November 17
More News related to Downgrades
- Sidoti & Co Downgrades Innophos Holdings (IPHS) to Neutral
- Sidoti & Co Downgrades Tyler Technologies (TYL) to Neutral
- China BAK (CBAK) Shares Tumble Amid Q4 Results, Roth Capital Downgrade
- Canaccord Adams Downgrades Micromet (MITI) to Hold
- Credit Suisse Downgrades Pepco Holdings (POM) to Neutral
BMO Capital downgrades Gilead Sciences (Nasdaq: GILD) from Outperform to Market Perform.
Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life-threatening infectious diseases.
Related Categories
DowngradesStocks Mentioned
+0.19Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
